Scientific article
OA Policy
English

Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists

Published inTranslational lung cancer research, vol. 10, no. 4, p. 1960-1968
Publication date2021
Abstract

Stage III N2 non-small cell lung cancer (NSCLC) is a very heterogeneous disease associated with a poor prognosis. A number of therapeutic options are available for patients with Stage III N2 NSCLC, including surgery [with neoadjuvant or adjuvant chemotherapy (CTx)/neoadjuvant chemoradiotherapy (CRT)] or CRT potentially followed by adjuvant immunotherapy. We have no clear evidence demonstrating a significant survival benefit for either of these approaches, the selection between treatments is not always straightforward and can come down to physician and patient preference. The very heterogeneous definition of resectability of N2 disease makes the decision-making process even more complex.

Keywords
  • Non-small cell lung cancer (NSCLC)
  • Decision-making
  • Radiotherapy
  • Stage III N2 lung cancer
  • Surgery
Citation (ISO format)
GLATZER, Markus et al. Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists. In: Translational lung cancer research, 2021, vol. 10, n° 4, p. 1960–1968. doi: 10.21037/tlcr-20-1210
Main files (1)
Article (Published version)
Identifiers
Journal ISSN2218-6751
157views
57downloads

Technical informations

Creation09/06/2021 15:30:00
First validation09/06/2021 15:30:00
Update time16/03/2023 01:37:26
Status update16/03/2023 01:37:24
Last indexation31/10/2024 23:31:37
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack